EVALUATING THE EFFICACY AND SAFETY OF TOPICAL DIFLUPREDNATE IN PATIENTS WITH CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Parul Yadav, Shakha, Sanjay Mishra et al.
✦ AI-curated · Sources linked
In 30 seconds
This pilot, open-label randomized controlled trial compared topical difluprednate, oral eplerenone, and observation in adults with chronic or relapsing central serous chorioretinopathy. Fifty-three participants were followed monthly for 3 months. Complete subretinal fluid resolution occurred in 90% (n = 18) of the difluprednate group, 45% (n = 9) of the eplerenone group, and 23% (n = 3) of the observation group (P < 0.001). Difluprednate also improved selected anatomical and retinal sensitivity measures, but ocular hypertension occurred in 30% of treated eyes.
Key findings
- Complete subretinal fluid resolution was 90% (n = 18) with difluprednate, 45% (n = 9) with eplerenone, and 23% (n = 3) with observation (P < 0.001).
- Difluprednate reduced subfoveal choroidal thickness and improved 3-mm microperimetry thresholds versus observation (P = 0.012 and P = 0.022, respectively).
- Ocular hypertension developed in 30% of difluprednate-treated eyes and was controlled with topical antiglaucoma medication.
Why it matters
The trial suggests topical difluprednate may improve fluid resolution and selected functional and anatomical outcomes in chronic central serous chorioretinopathy. The observed ocular hypertension is an important counterpoint, indicating that any potential benefit must be considered alongside pressure-related adverse effects. These findings add comparative evidence against eplerenone and observation, but require interpretation in light of the pilot design and short follow-up.
What to keep in mind
This was a pilot, open-label trial with monthly follow-up for 3 months; the abstract does not report longer-term outcomes.